Showing results (1871-1880 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|August 3, 2010
Sonodynamic and photodynamic mechanisms of action of the novel hypocrellin sonosensitizer, SL017: mitochondrial cell death is attenuated by 11, 12-epoxyeicosatrienoic acidHaitham E El-Sikhry, Gerald G Miller, Madi R Madiyalakan, et al.
Investigational New Drugs|August 5, 2010
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanomaSimon Pacey, Martin Gore, David Chao, et al.
Investigational New Drugs|June 24, 2010
Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cellsVivian Wai Yan Lui, Cecilia Pik Yuk Lau, Kakiu Ho, et al.
Investigational New Drugs|August 25, 2010
Salarin C, a member of the salarin superfamily of marine compounds, is a potent inducer of apoptosisNathalie Ben-Califa, Ashgan Bishara, Yoel Kashman, et al.
Investigational New Drugs|September 24, 2010
The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activityNataly Tarasenko, Gania Kessler-Icekson, Pnina Boer, et al.
Investigational New Drugs|October 6, 2010
Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancerJae-Heon Jeong, So-Youn Jung, In Hae Park, et al.
Investigational New Drugs|February 3, 2011
The notorious "drug lag" for oncology drugs in JapanKan Yonemori, Akihiro Hirakawa, Masashi Ando, et al.
Investigational New Drugs|January 13, 2011
A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancerXin Zhao, Kai Mei, Xiaohong Cai, et al.
Investigational New Drugs|January 13, 2011
Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation designAmye Tevaarwerk, George Wilding, Jens Eickhoff, et al.
Investigational New Drugs|January 4, 2011
TRAIL shows potential cardioprotective activityBarbara Toffoli, Stella Bernardi, Riccardo Candido, et al.
Pageof 372